NDA 20-926/S-002

GelTex Pharmaceuticals, Inc.
Attention: Ms. Martha Carter
Vice President, Regulatory Affairs
153 Second Avenue
Waltham, MA 02451

Dear Ms. Carter:

Please refer to your supplemental new drug application dated July 2, 1999, received July 6, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Renagel (sevelamer hydrochloride) Capsules, 403 mg. We also note that this submission addresses your Phase 4 commitment to perform *in vitro* and/or human *in vivo* drug interaction studies.

We acknowledge receipt of your submissions dated November 8 and 15, 1999, and March 17 and 27, and May 1, 2000.

This supplemental new drug application provides for changes to the DOSAGE AND ADMINISTRATION AND PRECAUTIONS (AGeneral@ and ADrug interactions@) sections. In the DOSAGE AND ADMINISTRATION section a new dosage regimen is added for patients switching from calcium acetate to Renagel Capsules, and in the PRECAUTIONS section drug interaction information is added for digoxin, warfarin, enalopril, and metoprolol.

We have completed the review of this supplemental application and Phase 4 data, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter. Also, we conclude that the above Phase 4 commitment has been fulfilled.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted May 1, 2000).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-926/S-002." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an

assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have not fulfilled the requirements of 21 CFR 314.55; however on November 15, 1999, you submitted a pediatric drug development plan. We are deferring any decision on your pediatric drug development plan until March 31, 2001, when your pilot study has been completed, and we have reviewed it.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the Division of Metabolic and Endocrine Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Randy Hedin, R.Ph., Senior Regulatory Management Officer, at (301) 827-6392.

Sincerely,

John K. Jenkins, M.D.
Acting Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II

Center for Drug Evaluation and Research